Motivational Deficits and Negative Symptoms in Schizophrenia: Concepts and Assessments

Reddy, L. Felice; Horan, William P.; Green, Michael F.

doi:10.1007/7854_2015_379

Cited by 36 publications

(33 citation statements)

References 79 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oxytocin may impact some of these deficits but not others, in which case investigating specific symptoms could prove useful. This is consistent with growing support in recent years for dividing negative symptoms into two distinct elements: 1) an experiential dimension comprised of avolition, anhedonia, and asociality; and, 2) an expressivity dimension comprised of restricted affect and poverty of speech (Reddy et al, 2015). …”

Section: Oxytocin Effects On Other Deficits In Schizophreniasupporting

confidence: 88%

Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward

Bradley

Woolley

2017

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Schizophrenia is a severe mental illness that causes major functional impairment. Current pharmacologic treatments are inadequate, particularly for addressing negative and cognitive symptoms of the disorder. Oxytocin, a neuropeptide known to moderate social behaviors, has been investigated as a potential therapeutic for schizophrenia in recent years. Results have been decidedly mixed, leading to controversy regarding oxytocin's utility. In this review, we outline several considerations for interpreting the extant literature and propose a focused agenda for future work that builds on the most compelling findings regarding oxytocin effects in schizophrenia to date. Specifically, we examine underlying causes of heterogeneity in randomized clinical trials (RCTs) conducted thus far and highlight the complexity of the human oxytocin system. We then review evidence of oxytocin's effects on specific deficits in schizophrenia, arguing for further study using objective, precise outcome measures in order to determine whether oxytocin has the potential to improve functional impairment in schizophrenia.

show abstract

Section: Oxytocin Effects On Other Deficits In Schizophreniasupporting

confidence: 88%

Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward

Bradley

Woolley

2017

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

show abstract

“…There were no significant associations between DD and other substances, symptoms, or antipsychotic medication dosages. Given the conceptual link between reward processing and negative symptoms (Reddy, Horan, et al, 2016), it is somewhat puzzling that alterations in DD, particularly on the experiential task, did not significantly correlate with higher clinically rated negative symptoms. Although some studies have found that neuroscience-based reward and decision making tasks are associated with negative symptoms (e.g., Barch, Treadway, & Schoen, 2014; Gold et al, 2013; Strauss et al, 2014) a number of studies by our group and others failed to detect such relationships (see Green, Horan, Barch, & Gold, 2015; Horan et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Altered experiential, but not hypothetical, delay discounting in schizophrenia.

Horan¹,

Johnson²,

Green³

2017

Journal of Abnormal Psychology

Self Cite

View full text Add to dashboard Cite

Delay discounting (DD) is a future-oriented decision making process that refers to whether one is willing to forego a smaller, sooner reward for the sake of a larger, later reward. It can be assessed using hypothetical tasks, which involve choices between hypothetical rewards of varying amounts over delay periods of days to years, or experiential tasks, which involve receiving actual rewards in real time over delay periods of seconds to minutes. Initial studies in schizophrenia have only used hypothetical tasks and have been mixed in finding either elevated or normal levels of DD. 131 outpatients with schizophrenia and 70 healthy controls completed hypothetical and experiential DD tasks involving monetary rewards, and the schizophrenia group was re-tested after four weeks. Although both groups showed qualitatively similar hyperbolic discounting functions on both tasks, they showed a quantitative DD difference. The schizophrenia showed higher DD than controls on the experiential task but normal DD on the hypothetical task. This pattern was not attributable to a range of potential confounds, including smoking status, substance use disorder status, or neurocognition. It was also not attributable to differences in the test-retest reliability, which was good for both tasks. The schizophrenia group’s robust pattern of altered experiential but normal hypothetical task performance points to key factors that may contribute to impaired DD in this disorder. These may include increased valuation of small (but not large) monetary rewards, or a hyper-sensitivity to costs associated with waiting inactively for those rewards.

show abstract

“…Given our results, one potentially promising pathway for developing negative symptom treatments is to enhance DLPFC-mediated cognitive control function in rewarding situations in order to improve functioning outcomes in schizophrenia. As recently reviewed by Reddy et al (2015), there are few effective negative symptom treatments and/or interventions in the field. Only a few preliminary studies exist on this topic (reviewed in Elis, Caponigro, & Kring, 2013).…”

Section: Discussionmentioning

confidence: 99%

Frontal-striatum dysfunction during reward processing: Relationships to amotivation in schizophrenia.

Chung

Deanna

2016

Journal of Abnormal Psychology

View full text Add to dashboard Cite

Schizophrenia is characterized by deficits of context processing, thought to be related to dorsolateral prefrontal cortex (DLPFC) impairment. Despite emerging evidence suggesting a crucial role of the DLPFC in integrating reward and goal information, we do not know whether individuals with schizophrenia can represent and integrate reward-related context information to modulate cognitive control. To address this question, thirty-six individuals with schizophrenia (n=29) or schizoaffective disorder (n=7) and twenty-seven healthy controls performed a variant of response conflict task (Padmala and Pessoa, 2011) during fMRI scanning, in both baseline and reward conditions, with monetary incentives on some reward trials. We used a mixed state-item design that allowed us to examine both sustained and transient reward effects on cognitive control. Different from predictions about impaired DLPFC function in schizophrenia, we found an intact pattern of increased sustained DLPFC activity during reward vs. baseline blocks in individuals with schizophrenia at a group level but blunted sustained activations in the putamen. Contrary to our predictions, individuals with schizophrenia showed blunted cue-related activations in several regions of the basal ganglia responding to reward-predicting cues. Importantly, as predicted, individual differences in anhedonia/amotivation symptoms severity were significantly associated with reduced sustained DLPFC activation in the same region that showed overall increased activity as a function of reward. These results suggest that individual differences in motivational impairments in schizophrenia may be related to dysfunction of the DLPFC and striatum in motivationally salient situations.

show abstract

Motivational Deficits and Negative Symptoms in Schizophrenia: Concepts and Assessments

Cited by 36 publications

References 79 publications

Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward

Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward

Altered experiential, but not hypothetical, delay discounting in schizophrenia.

Frontal-striatum dysfunction during reward processing: Relationships to amotivation in schizophrenia.

Contact Info

Product

Resources

About